EMD Millipore Opens New R&D Center - Pharmaceutical Technology

Latest Issue

Latest Issue
PharmTech Europe

EMD Millipore Opens New R&D Center
The facility, which includes state-of-the-art formulation, analytical and synthetic laboratories as well as a customer training center, will focus on bioavailability enhancement and oral dosage formulations.

EMD Millipore announced that it has opened a new R&D center for formulation in Darmstadt, Germany, which combines state-of-the-art formulation, analytical and synthetic laboratories and a customer training center in a single facility.

With EMD Millipore’s expertise in developing oral dosage formulations and drug delivery systems, the center will focus on addressing bioavailability and formulation challenges by using the company’s portfolio of innovative technologies and products. It will provide hands-on support to assist customers in their drug development.

EMD Millipore’s core areas are inorganic carriers, solid dispersion formulation techniques and excipients for controlled release, with technologies in granulation, tableting, film coating, direct compression and freeze drying.


blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
| Weekly

Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans

Click here